A Clinical Investigation to Assess the Performance of a Polyurethane Condom Versus a Latex Condom in Healthy Monogamous Couples
Study Details
Study Description
Brief Summary
This investigation is designed to evaluate the performance rate of a polyurethane (PU) condom versus a standard natural rubber latex (NRL) condom.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
In this clinical investigation, a new PU male condom (test condom) will be evaluated against a marketed NRL male condom (reference condom). This clinical investigation will also evaluate the in-use tolerance of the test and reference condoms.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Polyurethane (PU) condom Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation. |
Device: Polyurethane (PU) condom
A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
Device: Natural Rubber Latex (NRL) condom
A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
|
| Experimental: Natural Rubber Latex (NRL) condom Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation. |
Device: Polyurethane (PU) condom
A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
Device: Natural Rubber Latex (NRL) condom
A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
|
Outcome Measures
Primary Outcome Measures
- Compared clinical failure rate of condom use between the test condom group and the reference condom group [within 2 hours following each coital act for each condom use]
Clinical failure rate is calculated as the number of condoms with at least 1 acute clinical failure event divided by the number of condoms used during intercourse, reported as a percentage. Clinical failure events, defined in ISO 29943-1:2017, will be reported by subjects.
Secondary Outcome Measures
- Performance (clinical slippage rate) of the Polyurethane (PU) condom [within 2 hours following each coital act for each condom use]
Clinical slippage rate is calculated as the number of condoms with at least 1 clinical slippage event divided by the number of condoms used during intercourse, reported as a percentage. Clinical slippage events, defined in ISO 29943-1:2017, will be reported by subjects. A clinical slippage is defined as a condom slipping off completely during intercourse or during withdrawal from the vagina. Slippage that occur because the user failed to hold onto the condom at the base of the penis during withdrawal and/ or because the user delayed withdrawal after sex are to be record as "non-clinical slippage", these events are considered user failures.
- Performance (clinical slippage rate) of the Natural Rubber Latex (NRL) condom [within 2 hours following each coital act for each condom use]
Clinical slippage rate is calculated as the number of condoms with at least 1 clinical slippage event divided by the number of condoms used during intercourse, reported as a percentage. Clinical slippage events, defined in ISO 29943-1:2017, will be reported by subjects. A clinical slippage is defined as a condom slipping off completely during intercourse or during withdrawal from the vagina. Slippage that occur because the user failed to hold onto the condom at the base of the penis during withdrawal and/ or because the user delayed withdrawal after sex are to be record as "non-clinical slippage", these events are considered user failures.
- Performance (clinical breakage rate) of the Polyurethane (PU) condom [within 2 hours following each coital act for each condom use]
Clinical failure rate is calculated as the number of condoms with at least 1 acute clinical failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. Clinical failure events, defined in ISO 29943-1:2017, will be reported by subjects.
- Performance (clinical breakage rate) of the Natural Rubber Latex (NRL) condom [within 2 hours following each coital act for each condom use]
Clinical failure rate is calculated as the number of condoms with at least 1 acute clinical failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. Clinical failure events, defined in ISO 29943-1:2017, will be reported by subjects.
- Incidence of treatment-emergent adverse events and adverse device effects, defined in MEDDEV 2.7/3 [12 weeks]
- Subject's experience on the use of each type of condoms [Acceptability and Tolerability [12 weeks]
Acceptability and tolerability as assessed by subject perceived questionnaires (designed by following ISO 29943-1)
Eligibility Criteria
Criteria
Main Inclusion Criteria:
-
A male and a female subject aged: 18 - 60 years inclusive.
-
All subjects must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months.
-
All couples must be sexually active and agree to have penile-vaginal intercourse with a frequency sufficient to meet protocol requirements (a minimum of 5 coital acts over 4 weeks).
-
The female partner should already be on an established highly effective form of non-barrier contraception, unless post-menopausal.
-
Couples must agree not to use drugs or non-investigational devices that can affect sexual performance.
Main Exclusion Criteria:
-
Either partner is or becomes aware of an allergy or sensitivity to the ingredients of the test products, including the test or reference condoms.
-
Either partner has a pre-existing skin condition (severe eczema/ psoriasis) or systemic allergic reactions or as confirmed by the subject and physical examination.
-
Either partner that needs to use condoms for a specific sexually transmitted infection (STI) protection e.g. discordance for Human Immunodeficiency Virus (HIV) or herpes.
-
Subjects that have previous or planned genital surgery, that in the opinion of the Investigator would consider the subject unsuitable to participate in the clinical investigation e.g. laser for abnormal smear.
-
Male partners that have known erectile or ejaculatory dysfunction.
-
A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the investigator, deems the partner unsuitable for the investigation.
-
Any subject who has clinical symptoms or signs of a sexually transmitted diseases (STD) or HIV/ AIDS or has a previous history of high-risk behaviour as judged by the investigator.
-
Female partner using medication which in the investigator's opinion would affect vaginal mucosal secretion, such as Chlorpheniramine at any time in the 14 days (or 5 half-lives of the drug, whichever is longer) before first condom use.
-
A male partner with abnormal penile anatomy that would, in the opinion of the investigator, affect the ability to keep the condom in place during intercourse.
-
Either partner intends to continue to use antihistamines, anti-inflammatory drugs or pain killers for the duration of the investigation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | King Chulalongkorn Memorial Hospital | Bangkok | Thailand |
Sponsors and Collaborators
- Reckitt Benckiser Healthcare (UK) Limited
- Novotech (Australia) Pty Limited
Investigators
- Principal Investigator: Unnop Jaisamrarn, MD, King Chulalongkorn Memorial Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1003201